CVS Health CorporationNYSE: CVS
Health Care · Health Care Services
$98.92
-0.25%
Vol: 3.2M
Research Digest
Thursday, June 18, 2026
CVS Health hits 52-week high above $100 as GLP-1 drug coverage expansion and Salesforce AI partnership lift analyst price targets.
CVS Health reached a new 52-week high of $100.55 and traded near $101.96 in mid-June 2026, up roughly 26.6% year-to-date. The catalyst is a dual drug coverage expansion: CVS Caremark will add Zepbound back to preferred commercial formularies on October 1, 2026, and lifted the new-to-market block on Eli Lilly's oral GLP-1 Foundayo starting June 1. In parallel, CVS is rolling out the Salesforce Agentforce Health AI platform across Aetna and CVS Caremark call centers to reduce cost and improve service. Mizuho raised its price target to $115 from $110 on June 8, and the Street consensus stands at ~$103 with 18 Buy ratings and no Sells. The risk is continued managed-care margin pressure and execution of the broader health-services strategy transformation.
Previous Market Intelligence
13 daysJun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21CVS Health stock has surged about 24% in the past month as analysts raised price targets following Q1 earnings beat and raised 2026 guidance.Positive▶
CVS Health stock has risen about 24% over the past month on the strength of Q1 2026 results released May 6 and subsequent analyst upgrades. Q1 revenue of $100.43 billion beat the $94.99 billion estimate and EPS of $2.57 topped the $2.21 consensus, with all segments — Aetna, retail pharmacy and health services — beating expectations. CVS raised full-year 2026 adjusted EPS guidance to $7.30-$7.50 (from $7.00-$7.20) and now expects revenue of at least $405 billion (up from $400 billion). Multiple analysts raised targets: RBC Capital to $107 from $90, Evercore ISI to $105 from $100, and Truist to $102 from $98. On May 14, stockholders approved a new 2026 Incentive Compensation Plan. CVS also announced its Health100 technology subsidiary leveraging Google Cloud AI to deliver an integrated healthcare engagement platform. Shares trade around $95.71.
May 20CVS Health blows past Q1 estimates and raises 2026 guidance; analysts hike PTs across the boardPositive▶
CVS Health reported Q1 2026 revenue of $100.43B (vs $94.99B est) and EPS of $2.57 (vs $2.21 est), with all segments (Aetna insurer, retail pharmacy, health services) beating Wall Street. The company raised full-year EPS guidance to $7.30-$7.50 and revenue to at least $405B (up from $400B). The print extends CEO David Joyner's turnaround, which has cut $2B in costs and closed underperforming stores. CVS also unveiled Health100, a Google Cloud AI-powered health services subsidiary, and stockholders approved a new 2026 Incentive Compensation Plan on May 14. Analysts responded with PT hikes: RBC to $107 from $90, Evercore ISI to $105 from $100, BofA to $100 from $97.
May 19CVS Health stock hits 52-week high after Q1 2026 earnings beat and raised full-year guidancePositive▶
CVS Health reported Q1 2026 results on May 6 with revenue of $100.4 billion (up 6.2% YoY) and adjusted EPS of $2.57, both topping estimates. The company raised its full-year 2026 adjusted EPS outlook to $7.30-$7.50 and revenue guidance to at least $405 billion. Aetna's medical benefit ratio improved meaningfully to 84.6% from 87.3%, signaling progress in the insurance turnaround. Multiple analysts raised price targets in May, including RBC to $107, Evercore ISI to $105, and Truist to $102. CVS also launched Health100, an AI-powered healthcare engagement subsidiary in partnership with Google Cloud. Sentiment is strongly positive as the turnaround appears on track.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15CVS raises 2026 EPS guidance to $7.30-$7.50 after Q1 beat; faces new Rhode Island PBM lawsuit and prior $117.7M Medicare Advantage fraud settlementPositive▶
CVS Health reported Q1 2026 revenue up 6.2% YoY to $100.4B with adjusted EPS of $2.57 (vs. $2.25 prior year) and raised full-year adjusted EPS guidance to $7.30-$7.50 plus operating cash flow to at least $9.5B. Drivers included improved Health Care Benefits operating income, better Aetna medical cost management, and increased Rx volume from Rite Aid asset acquisitions. Morgan Stanley raised its price target to $106 from $93 (Overweight) and TD Cowen lifted to $110 from $105 (Buy). However, on May 7 the Rhode Island Attorney General filed suit against CVS Caremark and other PBMs alleging unfair and deceptive practices that increase drug costs. CVS also recently agreed to a $117.7M Medicare Advantage fraud settlement. Stock closed up 3.10% on May 13 in continued post-earnings strength. Risk: ongoing PBM regulatory and legal exposure could weigh on the Caremark segment.
May 14CVS Health shares surge 3.31% on May 12 hitting new 52-week high of $92.77; JPMorgan raises PT to $111 from $101 with Overweight rating amid 6-day winning streak (+22%).Positive▶
CVS Health shares surged 3.31% on May 12, 2026, hitting a new 52-week high of $92.77, extending a 6-day winning streak that delivered cumulative 22% gains. The rally followed JPMorgan raising its price target to $111 from $101 with an Overweight rating. Q1 2026 results released May 6 showed all segments — Aetna insurance, retail pharmacy, and health services — beating estimates; revenue rose 6.2% YoY to $100.4B, GAAP diluted EPS was $2.30, Adjusted EPS $2.57, and net income climbed 66% YoY to ~$3B. Full-year 2026 guidance was raised to $7.30-$7.50 adjusted EPS and revenue of at least $405B (up from $400B). CVS also launched Health100, an AI engagement platform with Google Cloud. Risks include the May 7 Rhode Island Attorney General lawsuit against CVS Caremark and other PBMs alleging unfair and deceptive practices that increase prescription drug costs, plus ongoing GLP-1/obesity drug cost pressures cited by the CEO on May 12.
May 13CVS Health hit a new 52-week high of $92.77 after Q1 2026 revenue of $100.4B (+6%) and net income of $3B (+66%); raised 2026 EPS guidance to $7.30-$7.50.Positive▶
CVS Health stock surged more than 7% on May 6, 2026 after Q1 2026 results beat estimates across every segment. Revenue rose 6% to $100.4B and net income came in at just under $3B, up 66% YoY. The medical benefit ratio improved to 84.6% from 87.3%. Aetna, retail pharmacy, and health services all surpassed expectations. The company raised 2026 guidance to $7.30-$7.50 EPS and revenue of at least $405B (up from $400B). The stock hit a 52-week high of $92.77 on May 11, with YTD returns of 16%. EVP Tilak Mandadi sold 69,551 shares on May 8 at an average of $89.58 for $6.23M total.
May 12CVS Health shares jumped 7.7% after Q1 2026 beat ($100.4B revenue, $2.57 adjusted EPS vs $2.21 consensus) and a guidance raise, but Rhode Island AG sued Caremark on May 7 over alleged PBM practices.Positive▶
CVS reported Q1 2026 revenue of $100.4 billion (up 6.2% YoY) and adjusted EPS of $2.57 versus $2.21 consensus, prompting a guidance raise: adjusted EPS to $7.30-$7.50 (from $7.00-$7.20) and revenue to at least $405 billion. The standout was Aetna's medical benefit ratio dropping to 84.6% from 87.3% a year earlier. Shares jumped roughly 7.7% post-print and traded to a new 52-week high near $86.89. The company also unveiled Health100, a Google Cloud-powered health technology subsidiary. Offsetting risk: on May 7 the Rhode Island Attorney General filed a lawsuit against CVS Caremark and other PBMs alleging unfair and deceptive practices that raise drug costs.
May 11CVS Health Q1 2026 earnings crushed estimates and raised full-year EPS guidance to $7.30-$7.50, sending shares up ~8% to a new 52-week high.Positive▶
On May 6, 2026, CVS Health reported adjusted EPS of $2.57 vs. $2.21 consensus (+16.3% beat) and revenue of $100.4B (+5.7% beat), with shares jumping 8.28% pre-market to $85.35 and later setting a new 52-week high near $86.89. The company raised full-year 2026 guidance: adjusted EPS to $7.30-$7.50 (from $7.00-$7.20), revenue to at least $405B (from $400B), and operating cash flow to at least $9.5B. Aetna's medical benefit ratio improved sharply to 84.6% from 87.3% YoY, the key driver of the beat. CVS also unveiled Health100, a new Google Cloud AI-powered healthcare engagement subsidiary. All segments (Aetna, retail pharmacy, health services) beat expectations. Risk: Aetna MBR improvement must be sustainable to justify the re-rating.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.